share_log

8-K: ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

8-K: ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

8-K:ENDRA 生命科学公布2024年第三季度财务业绩并提供业务最新情况
美股SEC公告 ·  2024/11/16 05:10

Moomoo AI 已提取核心信息

ENDRA Life Sciences reported Q3 2024 financial results with a net loss of $2.4M, compared to $3.1M in Q3 2023. Operating expenses decreased 52% YoY to $1.5M, primarily due to reduced general and administrative spending. The company ended the quarter with $4.7M in cash.The company made significant progress in its clinical initiatives, accelerating subject recruitment with nearly 40 subjects enrolled or being scanned in the past two months. ENDRA activated a TAEUS system at LMU University Hospital in Germany for post-market clinical study and expanded its patent portfolio to 82 issued patents globally.Management implemented cost-cutting measures, achieving $3.1M in annualized savings while refocusing resources on clinical and regulatory activities to support future FDA De Novo submission. The company also advanced its TAEUS platform by introducing new AI and machine learning features to improve data accuracy and operator ease-of-use.
ENDRA Life Sciences reported Q3 2024 financial results with a net loss of $2.4M, compared to $3.1M in Q3 2023. Operating expenses decreased 52% YoY to $1.5M, primarily due to reduced general and administrative spending. The company ended the quarter with $4.7M in cash.The company made significant progress in its clinical initiatives, accelerating subject recruitment with nearly 40 subjects enrolled or being scanned in the past two months. ENDRA activated a TAEUS system at LMU University Hospital in Germany for post-market clinical study and expanded its patent portfolio to 82 issued patents globally.Management implemented cost-cutting measures, achieving $3.1M in annualized savings while refocusing resources on clinical and regulatory activities to support future FDA De Novo submission. The company also advanced its TAEUS platform by introducing new AI and machine learning features to improve data accuracy and operator ease-of-use.
ENDRA Life Sciences报告了2024年第三季度的财务结果,净亏损240万美元,较2023年第三季度的310万美元有所减少。营业费用同比下降52%,降至150万美元,主要由于一般和行政支出的减少。该公司季度末现金余额为470万美元。该公司在临床项目上取得了重大进展,在过去两个月中,加速了受试者招募,近40名受试者已经入组或正在扫描。ENDRA在德国LMU大学医院启动了TAEUS系统进行市场后临床研究,并将其全球专利组合扩大至82项已授予专利。管理层实施了削减成本的措施,实现了310万美元的年度节省,同时将资源重新聚焦于临床和监管活动,以支持未来FDA De Novo提交。该公司还通过引入新的人工智能和机器学习功能来改进数据准确性和运营商的易用性,进一步推进其TAEUS平台。
ENDRA Life Sciences报告了2024年第三季度的财务结果,净亏损240万美元,较2023年第三季度的310万美元有所减少。营业费用同比下降52%,降至150万美元,主要由于一般和行政支出的减少。该公司季度末现金余额为470万美元。该公司在临床项目上取得了重大进展,在过去两个月中,加速了受试者招募,近40名受试者已经入组或正在扫描。ENDRA在德国LMU大学医院启动了TAEUS系统进行市场后临床研究,并将其全球专利组合扩大至82项已授予专利。管理层实施了削减成本的措施,实现了310万美元的年度节省,同时将资源重新聚焦于临床和监管活动,以支持未来FDA De Novo提交。该公司还通过引入新的人工智能和机器学习功能来改进数据准确性和运营商的易用性,进一步推进其TAEUS平台。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息